Literature DB >> 16021330

Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.

Shweta Singh1, Toshimitsu Suzuki2, Akira Uchiyama3, Satoko Kumada3, Nobuko Moriyama4, Shinichi Hirose5, Yukitoshi Takahashi6, Hideo Sugie7, Koichi Mizoguchi6, Yushi Inoue6, Kazue Kimura8, Yukio Sawaishi9, Kazuhiro Yamakawa10, Subramaniam Ganesh1.   

Abstract

Lafora disease (LD) is a rare autosomal recessive genetic disorder characterized by epilepsy, myoclonus, and progressive neurological deterioration. LD is caused by mutations in the EMP2A gene encoding a protein phosphatase. A second gene for LD, termed NHLRC1 and encoding a putative E3 ubiquitin ligase, was recently identified on chromosome 6p22. The LD is relatively common in southern Europe, the Middle East, and Southeast Asia. A few sporadic cases with typical LD phenotype have been reported from Japan; however, our earlier study failed to find EPM2A mutations in four Japanese families with LD. We recruited four new families from Japan and searched for mutations in EPM2A . All eight families were also screened for NHLRC1 mutations. We found five independent families having novel mutations in NHLRC1. Identified mutations include five missense mutations (p.I153M, p.C160R, p.W219R, p.D245N, and p.R253K) and a deletion mutation (c.897insA; p.S299fs13). We also found a family with a ten base pair deletion (c.822-832del10) in the coding region of EPM2A. In two families, no EPM2A or NHLRC1 mutation was found. Our study, in addition to documenting the genetic and molecular heterogeneity observed for LD, suggests that mutations in the NHLRC1 gene may be a common cause of LD in the Japanese population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021330     DOI: 10.1007/s10038-005-0263-7

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  27 in total

1.  Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.

Authors:  S Ganesh; K Shoda; K Amano; A Uchiyama; S Kumada; N Moriyama; S Hirose; K Yamakawa
Journal:  Mol Cell Probes       Date:  2001-10       Impact factor: 2.365

2.  A novel repeat domain that is often associated with RING finger and B-box motifs.

Authors:  F J Slack; G Ruvkun
Journal:  Trends Biochem Sci       Date:  1998-12       Impact factor: 13.807

Review 3.  The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions.

Authors:  D N Cooper; M Krawczak
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

4.  Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases.

Authors:  S Yokoi; J Austin; F Witmer; M Sakai
Journal:  Arch Neurol       Date:  1968-07

5.  Lafora disease due to EPM2B mutations: a clinical and genetic study.

Authors:  C Gómez-Abad; P Gómez-Garre; E Gutiérrez-Delicado; S Saygi; R Michelucci; C A Tassinari; S Rodríguez de Córdoba; J M Serratosa
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.

Authors:  Subramaniam Ganesh; Antonio V Delgado-Escueta; Toshiro Sakamoto; Maria Rosa Avila; Jesus Machado-Salas; Yoshinobu Hoshii; Takumi Akagi; Hiroshi Gomi; Toshimitsu Suzuki; Kenji Amano; Kishan Lal Agarwala; Yuki Hasegawa; Dong-Sheng Bai; Tokuhiro Ishihara; Tsutomu Hashikawa; Shigeyoshi Itohara; Eain M Cornford; Hiroaki Niki; Kazuhiro Yamakawa
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

7.  Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.

Authors:  Subramaniam Ganesh; Antonio V Delgado-Escueta; Toshimitsu Suzuki; Silvana Francheschetti; Concetta Riggio; Giuiliano Avanzini; Adrian Rabinowicz; Saeed Bohlega; Julia Bailey; Maria E Alonso; Astrid Rasmussen; Alfredo E Thomson; Adriana Ochoa; Aurelio J Prado; Marco T Medina; Kazuhiro Yamakawa
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

8.  The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q.

Authors:  J M Serratosa; A V Delgado-Escueta; I Posada; S Shih; I Drury; J Berciano; J A Zabala; M C Antúnez; R S Sparkes
Journal:  Hum Mol Genet       Date:  1995-09       Impact factor: 6.150

9.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.

Authors:  B A Minassian; J R Lee; J A Herbrick; J Huizenga; S Soder; A J Mungall; I Dunham; R Gardner; C Y Fong; S Carpenter; L Jardim; P Satishchandra; E Andermann; O C Snead; I Lopes-Cendes; L C Tsui; A V Delgado-Escueta; G A Rouleau; S W Scherer
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

10.  Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.

Authors:  Leonarda Ianzano; Edwin J Young; Xiao C Zhao; Elayne M Chan; M T Rodriguez; Maria V Torrado; Stephen W Scherer; Berge A Minassian
Journal:  Hum Mutat       Date:  2004-02       Impact factor: 4.878

View more
  14 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 2.  Lafora disease, seizures and sugars.

Authors:  D M Andrade; J Turnbull; B A Minassian
Journal:  Acta Myol       Date:  2007-07

Review 3.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy.

Authors:  S Singh; I Sethi; S Francheschetti; C Riggio; G Avanzini; K Yamakawa; A V Delgado-Escueta; S Ganesh
Journal:  J Med Genet       Date:  2006-09       Impact factor: 6.318

5.  Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2020-10-22       Impact factor: 5.590

Review 6.  Links between autophagy and disorders of glycogen metabolism - Perspectives on pathogenesis and possible treatments.

Authors:  Benjamin L Farah; Paul M Yen; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2019-11-21       Impact factor: 4.797

7.  Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Authors:  Luca Vignatelli; Francesca Bisulli; Federica Pondrelli; Lorenzo Muccioli; Laura Licchetta; Barbara Mostacci; Corrado Zenesini; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2021-08-16       Impact factor: 4.123

8.  Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease.

Authors:  M Traoré; G Landouré; W Motley; M Sangaré; K Meilleur; S Coulibaly; S Traoré; B Niaré; F Mochel; A La Pean; A Vortmeyer; H Mani; K H Fischbeck
Journal:  Neurogenetics       Date:  2009-03-26       Impact factor: 2.660

9.  Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.

Authors:  Ana M García-Cabrero; Gentzane Sánchez-Elexpuru; José M Serratosa; Marina P Sánchez
Journal:  Front Neurosci       Date:  2014-09-12       Impact factor: 4.677

Review 10.  Genetics of Lafora progressive myoclonic epilepsy: current perspectives.

Authors:  Miljana Kecmanović; Milica Keckarević-Marković; Dušan Keckarević; Galina Stevanović; Nebojša Jović; Stanka Romac
Journal:  Appl Clin Genet       Date:  2016-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.